Drugs Made In America Acquisition II Corp. (DMIIU) Stock Analysis
Drugs Made In America Acquisition II Corp.
▾ What's in the 37/100 risk score? (higher = riskier)
Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). See the Financial Health section for the full balance-sheet read.
How to read DMIIU
We are not publishing an intrinsic value for this one — the section below says exactly why. Everything on this page that comes straight from the filings and the tape is still here; treat the missing valuation as a known gap, not as a verdict on the business.
-
1
Reported earnings & margins ↓
What the company actually reported — unaffected by the valuation being held.
-
2
Balance sheet & book value ↓
Assets, liabilities and equity as filed.
-
3
Who's selling & betting against it ↓
Insider and short-interest behaviour needs no valuation model.
DMIIU's SEC filings give us limited machine-readable financials — common for some foreign or newly-listed filers that report under IFRS or file abbreviated statements. We can't run a full valuation on a partial dataset.
What to use instead: What we have parsed is shown below. As more complete filings arrive (or IFRS support lands), the valuation will populate.
How does DMIIU stack up against its closest peers?
We take the 8 same-industry companies most similar to DMIIU (similar size) and check what investors are paying for each dollar of their revenue (or profits). If DMIIU is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium.
▾ What's "EV / Sales" in plain English?
EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.
EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).
p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.
Bold middle number = median peer. Half the peers trade above it, half below. Computed over 8 same-industry peers; implausible multiples excluded.
⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.
▾ View peer list (8)
| Ticker | Company | Industry | Mcap | EV/Sales | EV/GP | EV/EBIT | FCF Yield |
|---|---|---|---|---|---|---|---|
| TACO | Berto Acquisition Corp. | SPACs | $393M | — | — | — | — |
| SSAC | SPACSphere Acquisition Corp. | SPACs | $182M | — | — | — | — |
| SOUL | Soulpower Acquisition Corp. | SPACs | $174M | — | — | — | — |
| TAVI | Tavia Acquisition Corp. | SPACs | $169M | — | — | — | — |
| WENC | West Enclave Merger Corp. | SPACs | $160M | — | — | — | — |
| LKSP | Lake Superior Acquisition Corp | SPACs | $159M | — | — | — | — |
| TRAD | APEX Tech Acquisition Inc. | SPACs | $142M | — | — | — | — |
| XFLH | XFLH Capital Corp | SPACs | $138M | — | — | — | — |
Quality & solvency checks
Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
The F-score compares two consecutive years of income, cash-flow and balance-sheet data. This filer has only 1 usable year, so there is no prior period to compare against. We show nothing rather than score a partial year against itself. The reported figures in the financial tables below are unaffected.
A standard discounted cash flowDCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
Full explanation → (DCF) valuation is not meaningful for Drugs Made In America Acquisition II Corp. (DMIIU) because its operating cash flow is negative, indicating it is not yet generating profits. To value this company, one would need to project its future revenue trajectory and margin expansion post-acquisition, as the model currently projects future cash flows from revenue growth. Investors are likely betting on the success of its eventual business combination. The biggest risk to our assumptions is that the current ratio is 0.09, meaning current liabilities significantly exceed liquid assets, which could hinder future operations or require further capital raises.
As of 4 days ago
Anatomy of a share
What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.
What's free cash flow / what do these mean?
Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.
Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.
Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.
Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.
What you actually need to decide
Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.
- Announcement of a definitive merger agreement
- Shareholder vote on the proposed business combination
- Financial performance of the acquired entity post-merger
Management & Leadership
Drugs Made In America Acquisition II Corp. is a Special Purpose Acquisition Company (SPAC). As such, it does not have an operating CEO in the traditional sense, but rather a management team focused on identifying and acquiring a target company. Limited executive data is available for the specific individuals leading this SPAC.
What They Make
Drugs Made In America Acquisition II Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It does not currently make or sell products; its 'customers' are the investors who purchase its shares, providing capital for a future acquisition.
End Markets
Revenue Drivers
Why Is It Priced Like This?
Why Customers Pay
What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.
The market is pricing DMIIU based on the expectation of a successful business combination, rather than current cash flows, as its operating cash flow is negative. The market may be assigning value to the potential for a high-growth target company in the 'Drugs Made In America' sector, which is not in the model, and the implied future revenue trajectory post-acquisition. The current ratio of 0.09 indicates a reliance on future capital or a successful merger to improve liquidity.
Business Model & Valuation
How They Make Money
The company funds itself primarily through equity raises from its initial public offering, as it is a SPAC and does not have ongoing operating cash flows. There are no dividends or buybacks at this stage.
Growth / Revenue DCF
Negative free cash flow: revenue/margin growth model used - standard FCF DCF is unreliable for companies still scaling.
Show advanced inputs
| Revenue Growth | 15.0% |
What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project net interest income and fee-income lines independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.
Maturity & Competitive Position
Moat Signals
Not applicable as a SPAC, as it has no operating revenue or EPSEPS — Earnings per share — net income divided by shares outstanding.
Why it matters: The basis for the P/E ratio. But "earnings" is an accountant's figure — easier to manipulate than cash flow.
Full explanation → trend prior to an acquisition.
Geography & Markets
As a SPAC, Drugs Made In America Acquisition II Corp. is typically headquartered in the US, with its focus on identifying a target company that may have operations globally, though exact geographic mix is not available from current data sources.
Geographic Risks
Market Signals
These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation → (14)70.7OverboughtBought up hard recently — stretched; pullbacks are common from here.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →BearishLine below signalThe fast trend is below the slow trend — short-term momentum is currently downward.
Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.
QUALITY
Data Quality & Risk Flags (5 notes — click to expand/collapse)
Guardrail Notes (5)
- FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
- INVARIANT: weighted IV is non-positive. Model may not be appropriate.
- Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
- Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).
- Extreme valuation gap (P/IV withheld — see the note above): result may be dominated by model assumptions, share count issues, or sector-specific dynamics. Treat as low confidence.
FINANCIALS
Financial Statements (5-year tables — click to expand)
From Drugs Made In America Acquisition II Corp.'s SEC filings (EDGAR).
Income (5yr)
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | — | 4.2M | $0.07 |
Cash Flow (5yr)
CapEx is approximated. This filer reports capital expenditure under a company-specific tag our parser cannot read, so the CapEx column uses total investing outflow instead. That includes acquisitions and investment purchases, so the free cash flow shown is a conservative (lower-bound) figure in years with large deals.
| Year | Operating CF | Investing outflow (capex proxy) | − SBC | Free Cash Flow |
|---|---|---|---|---|
| 2025 | -1.0M | 500.0M | — | -501.0M |
How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.
Balance Sheet
| Total Assets | 505.0M |
| Total Liabilities | 17.8M |
| Equity | -17.8M |